Home/ Stocks/ PPCB

Propanc Biopharma, Inc. Common Stock

PPCB XNAS

$2.35 +1.31 (+122.43%) ▲ 15-min delayed

Open

$3.51

High

$4.13

Low

$2.25

Volume

85.05M

Market Cap

$2.44M

About Propanc Biopharma, Inc. Common Stock

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 2 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2026	$0	$-6,360,336	$-0.28
Q2 2026	$0	$-3,091,394	$-0.30
Q1 2026	$0	$-4,837,738	$-0.39

TickerDaily Coverage

Why Is Propanc Biopharma, Inc. Common Stock (PPCB) Stock Up 245.5% Today?

Penny Stocks Marcus Rivera · 3h ago

Propanc Biopharma (PPCB) stock ripped 245.5% on Thursday, August 27, 2026, closing at $3.72 after...

View All Coverage →

Get PPCB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Propanc Biopharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.